Latest news
Invitation to first quarter 2019 result presentation
Oslo, Norway, 30 April 2019 – PCI Biotech invites to a presentation of the company’s first quarter 2019 result on Wednesday 8 May 2019 at Oslo Cancer Cluster Innovation Park. Time: Wednesday 8 May, 08:30am – 09:30am CEST (local time). Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation Park, Ullernchausséen 64, […]
Annual Report 2018
Oslo, Norway, April 9, 2019 – The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2018 and the report is attached. The Annual Report 2018 is also available on the company’s website www.pcibiotech.com. For further information, please contact: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Per Walday, CEO, pw@pcibiotech.no, […]
Final confirmation of successful safety read-out in the Phase I Extension study
Oslo (Norway), 8 April 2019 – PCI Biotech (OSE: PCIB), a cancer focused clinical-stage company developing innovative therapeutics that address significant unmet medical needs today announced final confirmation of successful safety read-out for the Phase I Extension study in inoperable bile duct cancer patients which currently are left without effective local treatment options. The appointed […]